Coenzyme Q_{10} administration increases antibody titer in hepatitis B vaccinated volunteers – A single blind placebo‐ controlled and randomized clinical study
Affiliations: Vitamex AB, P.O. Box 715, SE‐601 16 Norrköping, Sweden | Dr. B. Lund Pharma Consulting, CH‐6914 Carona (Lugano), Switzerland | Department of Pharmacology University of Milan, Via Vanvitelli 32, I‐20129 Milan, Italy
Abstract: Persons involved in the study, 21 per treatment arm, were consuming ubiquinone (Q_{10}), 90 mg/day, 180 mg/day or placebo, for two weeks prior to hepatitis B vaccination. After 30 days this vaccination was repeated. Q_{10} was given as soft gelatin capsules containing 30 mg each. The consumption was continued throughout the study conducted for 90 days. Clinical observations and laboratory tests were performed throughout the study and no adverse effects were observed in any of the groups. Already after 30 days the two groups receiving Q_{10} showed a slightly higher titer of antibodies to hepatitis B surface antigen then the placebo group. This difference escalated and the immunopotentiating effect of Q_{10} was even more clear‐cut in the residual part of the study. In addition, a dose response did also seem to be present when comparing the 90 mg group with the 180 mg group. Statistics revealed that Q_{10} in the dose 180 mg/day is able to increase antibody response in vivo in humans vaccinated against hepatitis B with up to 57% (p=0.011).
Journal: Biofactors, vol. 9, no. 2-4, pp. 351-357, 1999
